Bayer Regeneron Eye Drug Meets Study Goal
By wchung | 11 May, 2026
Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Thursday their developing VEGF Trap-Eye drug met key vision improvement goals in a midstage study.
The drug is aimed at improving vision in patients with diabetic macular edema. The condition is a disease of the retina that affects individuals with diabetes and can lead to blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The companies also said VEGF Trap-Eye was well tolerated, and there were no drug-related serious adverse events.
Shares of Regeneron, which is based in Tarrytown, N.Y., closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
2/18/2010 8:18 AM NEW YORK (AP)
Recent Articles
- The Fastest Growing Asian American Communities Are in the South
- China's Factory Inflation Hit 45-Month High on Energy Price Shock
- China's Domestic Car Demand Stays Weak but Exports Strengthen
- Dua Lipa Sues Samsung for Using Her Image to Sell TVs
- Trump Rejects Iran's Counter to US Peace Proposal
- Bedtime Story: The Legend of Savitri and Satyavan
- Let's Not Do the Whole "China Virus" Thing Again
- Frayed Ties with Allies Likely to Be an Enduring Trump Legacy
- Thailand's SiamAI Denies Exporting US AI Servers to China
- China's Trade Surplus Grows on Strong April Exports Rebound